KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Capital Expenditures: 2013-2025

Historic Capital Expenditures for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $281,000.

  • Xenon Pharmaceuticals' Capital Expenditures fell 52.37% to $281,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 46.67%. This contributed to the annual value of $3.1 million for FY2024, which is 45.26% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Capital Expenditures of $281,000 as of Q3 2025, which was up 78.98% from $157,000 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Capital Expenditures high stood at $2.2 million for Q1 2023, and its period low was $43,000 during Q1 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median Capital Expenditures value was $590,000 (recorded in 2024), while the average stood at $833,909.
  • Over the last 5 years, Xenon Pharmaceuticals' Capital Expenditures had its largest YoY gain of 940.57% in 2023, and its largest YoY loss of 95.55% in 2023.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Capital Expenditures stood at $514,000 in 2021, then skyrocketed by 240.86% to $1.8 million in 2022, then slumped by 95.55% to $78,000 in 2023, then spiked by 903.85% to $783,000 in 2024, then plummeted by 52.37% to $281,000 in 2025.
  • Its Capital Expenditures stands at $281,000 for Q3 2025, versus $157,000 for Q2 2025 and $43,000 for Q1 2025.